Lanton is government affairs director for the American Association of Clinical Urology.
Biomarkers in urology: Policy and legislative advances
"The AACU has been discussing the evolution of state policy to ensure that biomarker testing, including PSA screening, is covered by payers," writes Ron Lanton, Esq.
Nivolumab/ipilimumab continues to show improved survival, durable response in aRCC
Mixed results reported for nivolumab/ipilimumab in cisplatin-ineligible mUC
EV plus pembrolizumab doubles CR rate vs chemotherapy in la/mUC
Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment